Sonidegib, also known as LDE‐225, is a synthetically derived, new molecular entity that exerts its function by binding and inhibiting Smo receptors and is the second Smo inhibitor approved by the FDA in 2015 for the treatment of patients with locally advanced BCC not amenable to curative surgery or radiation therapy [434–436]. Here, SMO is linked to skin basal cell carcinoma.